Capital Advisors Ltd’s Royalty Pharma RPRX Stock Holding History

Capital Advisors Ltd’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8K	Hold	149	–	–	﹤0.01%	896
2026 Q1	$7K	Hold	149	–	–	﹤0.01%	904
2025 Q4	$6K	Hold	149	–	–	﹤0.01%	918
2025 Q3	$5K	Hold	149	–	–	﹤0.01%	932
2025 Q2	$5K	Hold	149	–	–	﹤0.01%	932
2025 Q1	$5K	Hold	149	–	–	﹤0.01%	924
2024 Q4	$4K	Sell	149 -65	-30%	-$1.72K	﹤0.01%	976
2024 Q3	$6K	Hold	214	–	–	﹤0.01%	895
2024 Q2	$6K	Sell	214 -143	-40%	-$3.96K	﹤0.01%	887
2024 Q1	$11K	Buy	357 +158	+79%	+$4.66K	﹤0.01%	701
2023 Q4	$6K	Sell	199 -97	-33%	-$2.67K	﹤0.01%	804
2023 Q3	$8K	Buy	296 +82	+38%	+$2.44K	﹤0.01%	726
2023 Q2	$7K	Buy	214 +180	+529%	+$6.1K	﹤0.01%	762
2023 Q1	$1K	Buy	+34	New	+$1.26K	﹤0.01%	1102
2022 Q4	–	Sell	-9	Closed	–	–	1575
2022 Q3	$0	Buy	+9	New	+$384	﹤0.01%	1476
2022 Q2	–	Sell	-22	Closed	-$1K	–	1280
2022 Q1	$1K	Buy	22 +16	+267%	+$628	﹤0.01%	793
2021 Q4	$0	Buy	+6	New	+$233	﹤0.01%	918

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Advisors Ltd's RPRX Position: Q2 2026 in Review

Capital Advisors Ltd held its Royalty Pharma (RPRX) position steady in Q2 2026 at 149 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #896.

Capital Advisors Ltd first reported a position in RPRX in Q4 2021 and has held it in 17 quarters since. The position peaked at $11K in Q1 2024. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Capital Advisors Ltd held 149 shares of Royalty Pharma worth $8K as of Q2 2026.
Capital Advisors Ltd left its Royalty Pharma share count unchanged in Q2 2026.
Royalty Pharma made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #896 holding.
Capital Advisors Ltd first reported a position in Royalty Pharma in Q4 2021 and has held it in 17 quarters since.
Capital Advisors Ltd's Royalty Pharma position peaked at $11K in Q1 2024.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.